2021-17: MTHFR Polymorphism: Treatment Options for Depression

5 (2 votes)

2021-17: MTHFR Polymorphism:  Treatment Options for Depression

Depression is a significant contributor of chronic disability. At least half of adults with depressive symptoms do not experience symptom relief despite treatment. 70% with depressive symptoms have a polymorphism of MTHFR which leads to treatment resistance. Screening for and treating MTHFR polymorphism could lead to symptom relief from depression.


Presenter:
  Allyson Matney Neal, DNP, PMHNP-BC, PMHCNS-BC, CPNP

Disclosures:  The presenter and planners have no conflict of interest or commercial support to disclose.  Off-label uses will not be discussed during this presentation.


Session Length:
  38 minutes

Target Audience:  APRN


Learning Outcomes:
Upon completion of this presentation, the participant will be able to:

  1. Summarize the relationship between MTHFR polymorphism and depression.
  2. Identify patients that could benefit from addressing MTHFR polymorphism.
  3. Discuss screening and treatment related to MTHFR polymorphism and treatment resistant depression.

Keywords:  Homocysteine, Methionine Levels, Depression, Treatment


Continuing Nursing Education:
0.5 contact hours.  * In order to receive contact hours, you must: Listen to presentation, complete an evaluation, and earn a passing score on the post-test before the expiration date. You will have 5 tries to correctly answer the questions on the post-test and a score of 80% is required to pass. Once you have passed and completed an evaluation, the certificate will be generated online, available for you to print immediately. You cannot earn credit unless all steps are completed.

The American Psychiatric Nurses Association is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.


Originally Presented
APNA 31st Annual Conference
Phoenix, Arizona
Thursday, October 19, 2017
11:15am - 12:00pm

The contact hours for this session expire:  December 31, 2019

Components visible upon registration.